In the same way, canakinumab, a neutralizing mAb of IL-1β through competition for IL-1RI binding, is used to treat auto-inflammatory severe diseases and has been evaluated in COVID-19 patients [68,69,70,71]. This evidence concerns the gene IL1B and COVID-19.